Sara B. DeMauro,Haresh Kirpalani,Kristina Ziolkowski,Susan Hintz,Kristi Watterberg,Jean Lowe,Seetha Shankaran,Sanjay Chawla,Betty Vohr,Michael Msall,Carl D’Angio,Bradley A. Yoder,Khanh Lai,Sarah Winter,Tarah Colaizy,Stephanie Merhar,Carla M. Bann,Marissa Trotta,Jamie Newman,Aruna Natarajan,Abhik Das

Abstract:Bronchopulmonary dysplasia (BPD) affects up to half of extremely preterm infants, and is associated with adverse long-term respiratory, neurodevelopmental, and educational sequelae and costly health service and family economic outcomes. The NICHD Neonatal Research Network Hydrocortisone for Bronchopulmonary Dysplasia (BPD) Trial evaluated the efficacy and safety of hydrocortisone treatment to prevent BPD in high-risk infants. The trial enrolled 800 very preterm infants with respiratory failure and followed the participants until 2 years corrected age to assess safety of the trial intervention. Longer-term impacts of hydrocortisone exposure and severity of BPD on functional outcomes of high-risk infants remain unknown. The HYdrocortisone for BPD Respiratory and Developmental (HYBRiD) Outcomes Study extends follow-up of all surviving children enrolled in the Hydrocortisone for BPD Trial until early school age. It aims to characterize the childhood functional motor, cognitive, academic, and pulmonary outcomes of this large, well-phenotyped trial cohort.

The HYdrocortisone for Bronchopulmonary Dysplasia Respiratory and Developmental (HYBRiD) outcomes study: protocol for a longitudinal cohort study